EMEA call for interested parties – interaction with the Committee for Advanced Therapies (CAT)
16 July 2009
The Committee for Advanced Therapies (CAT) based at the EMEA play a central role in the assessment and scientific development of advanced therapy medicinal products (ATMPs), namely gene therapy, somatic cell therapy and tissue engineered products.
Recognising the need for effective dialogue and development of a working relationship with stakeholders in the field of ATMPs, the CAT hopes to develop a permanent forum for interaction with its interested parties.
Some examples may include:
- Participation in hearings with the CAT (general annual hearing or ad-hoc specific hearings) and its working parties;
- Proactive consultation in guideline development
The first CAT hearing is expected to be held on 11th September 2009.
For further information and to express interest, please refer to the website below: